ASP9801
/ Astellas, Tottori University
- LARVOL DELTA
Home
Next
Prev
1 to 8
Of
8
Go to page
1
May 20, 2024
KEYNOTE-B26: A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors
(clinicaltrials.gov)
- P1 | N=72 | Completed | Sponsor: Astellas Pharma Global Development, Inc. | Active, not recruiting ➔ Completed
Combination therapy • Metastases • Oncolytic virus • Trial completion • Oncology • Solid Tumor
February 16, 2024
KEYNOTE-B26: A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors
(clinicaltrials.gov)
- P1 | N=72 | Active, not recruiting | Sponsor: Astellas Pharma Global Development, Inc. | Trial completion date: Aug 2024 ➔ Apr 2024 | Trial primary completion date: Aug 2024 ➔ Apr 2024
Combination therapy • Metastases • Oncolytic virus • Trial completion date • Trial primary completion date • Oncology • Solid Tumor
April 05, 2023
KEYNOTE-B26: A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors
(clinicaltrials.gov)
- P1 | N=72 | Active, not recruiting | Sponsor: Astellas Pharma Global Development, Inc. | N=260 ➔ 72
Combination therapy • Enrollment change • IO biomarker • Metastases • Oncolytic virus • Oncology • Solid Tumor
March 09, 2023
KEYNOTE-B26: A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors
(clinicaltrials.gov)
- P1 | N=260 | Active, not recruiting | Sponsor: Astellas Pharma Global Development, Inc. | Recruiting ➔ Active, not recruiting
Enrollment closed • Oncology • Solid Tumor
March 22, 2022
A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors
(clinicaltrials.gov)
- P1 | N=260 | Recruiting | Sponsor: Astellas Pharma Global Development, Inc. | N=105 ➔ 260
Combination therapy • Enrollment change • IO biomarker • Oncolytic virus • Oncology • Solid Tumor
September 02, 2020
A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors
(clinicaltrials.gov)
- P1; N=105; Recruiting; Sponsor: Astellas Pharma Global Development, Inc.; Active, not recruiting ➔ Recruiting; Trial completion date: Mar 2023 ➔ Oct 2024; Trial primary completion date: Mar 2022 ➔ Oct 2024
Clinical • Enrollment open • Oncolytic Virus • Trial completion date • Trial primary completion date • Oncology • Solid Tumor
May 07, 2020
A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors
(clinicaltrials.gov)
- P1; N=105; Active, not recruiting; Sponsor: Astellas Pharma Global Development, Inc.; Recruiting ➔ Active, not recruiting
Clinical • Enrollment closed • Oncolytic Virus
June 27, 2019
A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors
(clinicaltrials.gov)
- P1; N=105; Recruiting; Sponsor: Astellas Pharma Global Development, Inc.; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Oncolytic Virus
1 to 8
Of
8
Go to page
1